Covidien Expands Device Portfolio for Endovascular Treatment of Peripheral Vascular Disease
PLYMOUTH, Minn.--(BUSINESS WIRE)--Sep 17, 2012--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the Viance™ Crossing Catheter and Enteer™ Re-entry System for treating chronic total occlusions (CTOs) endovascularly. The devices are now available in the United States, the European Union (EU) and other select international markets.
Viance(TM) Crossing Catheter: Covidien today announced the launch of its new Viance(TM) Crossing Catheter at the Cardiovascular and Interventional Radiological Society of Europe Annual Congress (Photo: Business Wire) “Management of the lower extremity CTO remains challenging for endovascular physicians,” said David B. Jessup, MD of PeaceHealth St. Joseph Medical Center in Bellingham, Washington. “Effective devices for CTO crossing and re-entry can expand the number of patients who have access to endovascular treatment of peripheral arterial disease, which may help patients avoid more invasive treatments and allow physicians to offer amputation-saving procedures.” For effective treatment, physicians must be able to successfully cross lesions. The new tools from Covidien are designed to enable access to the distal end of a lesion, allowing physicians to treat even the most challenging lesions endovascularly. Together, the Viance Crossing Catheter and the Enteer Re-entry System offer a solution that leverages the skill and finesse of the physician rather than brute force or capital equipment.
“Covidien now offers a unique solution for the treatment of CTOs,” said Brian Verrier, Vice President and General Manager, Peripheral Vascular, Covidien. “By adding these products to our market-leading peripheral portfolio, we strive to demonstrate our commitment to advancing the treatment of vascular disease worldwide by delivering innovation that achieves both clinical and economic value for our healthcare partners.” Competitive crossing devices rely on more aggressive cutting, grinding or pounding motions and can be more difficult to control. Moreover, the distinctive shape of the re-entry balloon enables it to self-orient within the vessel. No other product on the market utilizes this balloon technology for a re-entry system.
The announcement was made at the Cardiovascular and Interventional Radiological Society of Europe ( CIRSE 2012 ) Annual Congress.
ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 43,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50410865&lang=enCONTACT: Vascular Therapies David T. Young, 508-452-1644 Manager, External Communications firstname.lastname@example.org or Bruce Farmer, 508-452-4372 Vice President Public Relations email@example.com or Coleman Lannum, CFA, 508-452-4343 Vice President Investor Relations firstname.lastname@example.org or Todd Carpenter, 508-452-4363 Director Investor Relations email@example.com KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES SOURCE: Covidien Copyright Business Wire 2012 PUB: 09/17/2012 04:15 PM/DISC: 09/17/2012 04:15 PM http://www.businesswire.com/news/home/20120917006444/